Author Contributions: Dr Dyer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs N-K. Cheung, Zhang, and Lu contributed equally to the work.
Study concept and design: N-K. Cheung, Zhang, Tickoo, Pappo, Mardis, Wilson, Downing, Dyer.
Acquisition of data: N-K. Cheung, Zhang, Parker, Bahrami, Tickoo, Heguy, Federico, I. Cheung, Ding, Fulton, Ellison, Wilson.
Analysis and interpretation of data: N-K. Cheung, Zhang, Lu, Parker, Bahrami, Heguy, Pappo, Federico, Dalton, Ding, Wang, Chen, Becksfort, Wu, Billups, Ellison, Mardis, Wilson, Downing, Dyer.
Drafting of the manuscript: N-K. Cheung, Zhang, Parker, Bahrami, Heguy, Pappo, Federico, Dalton, Wu, Billups, Ellison, Downing, Dyer.
Critical revision of the manuscript for important intellectual content: N-K. Cheung, Zhang, Lu, Tickoo, Pappo, Federico, I. Cheung, Ding, Fulton, Wang, Chen, Becksfort, Mardis, Wilson, Downing, Dyer.
Statistical analysis: Zhang, Lu, Parker, Chen, Becksfort, Wu, Billups.
Obtained funding: N-K. Cheung, Wilson, Downing.
Administrative, technical, or material support: N-K. Cheung, Heguy, Federico, Dalton, I. Cheung, Fulton, Chen, Becksfort, Ellison, Mardis, Wilson, Downing, Dyer.
Study supervision: N-K. Cheung, Zhang, Pappo, Ding, Mardis, Wilson, Downing, Dyer.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr N-K. Cheung reported holding patents for monoclonal antibodies, beta-glucan, GD2 peptide mimetics, and methods for detecting residual disease and receiving royalties from United Therapeutics and Biotec Pharmacon. Dr Pappo reported serving as a consultant to Ziopharm. No other author reported disclosures.
Funding/Support: The whole genome sequencing was supported as part of the St Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. This work was supported in part by Cancer Center Support grant CA21765 from the National Cancer Institute; grants EY014867 and EY018599 from the National Institutes of Health (awarded to Dr Dyer); and the American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital. Dr Dyer is a Howard Hughes Medical Institute Early Career Scientist. This work also was supported by the Catie Hoch Foundation and the Robert Steel Foundation.
Role of the Sponsors: None of the funding sources played any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Additional Contributions: Michael Rusch, BS (St Jude Children's Research Hospital) provided annotation of the focal deletions identified in ATRX. Robert Huether, PhD (St Jude Children's Research Hospital) provided interpretation of the functional impact of the ATRX mutations based on protein structure modeling. Clayton Naeve, PhD (St Jude Children's Research Hospital) provided computational infrastructure for data analysis. Elizabeth Chamberlain, BA (Memorial Sloan-Kettering Cancer Center) provided assistance with clinical data management. No compensation was provided to the individuals listed in this section.